Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

BRAINZ PODCAST

What Is the Award-Winning "VIP Biohacking Method"? - Brainz Magazine Exclusive interview with Dr. Mark Hawass

22 Apr 2025

Description

Dr. Mark Hawass is an award-winning leader in chronic pain and arthritis treatment, revolutionizing patient care through his groundbreaking VIP Biohacking Method. After enduring 11 years of debilitating pain from a car accident, he invested over $500,000 in advanced medical training, determined to create a real solution beyond medications and surgery. Since launching Arthritis VIP in 2019, Dr. Hawass and his team have helped over 1,500 patients reclaim their mobility and quality of life, eliminating long wait times and addressing the root causes of pain with a 90% success rate. A former Medical Director and Chronic Pain Expert Trainer, he has trained over 100 physicians, developed medical curricula, and conducted clinical trials to advance treatment methodologies.Dr. Hawass challenges conventional medicine, advocating for proactive, regenerative solutions that empower patients to thrive, not just survive. His expertise has been recognized by Forbes, CityTV, Business Insider, and multiple innovation awards, cementing his reputation as a trusted authority in non-surgical pain relief.In this episode, we discover the following:   1. What is the award-winning "VIP Biohacking Method"?  2. What’s the best way to manage pain?  3. The most common misconception people have about joint pain and arthritis.  4. What people should and shouldn’t do to manage pain, and why prevention is better than a cure.With podcast host Mark SephtonHope you'll enjoy the episode! Hosted on Acast. See acast.com/privacy for more information.

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.